Editor's Pick
The firm plans to present data from a large validation study of the Signal-C early detection test later this year as it contemplates approval.
Ampel will use the signature to develop FibroGene, a fibromyalgia blood test that the company expects to launch next year.
New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions
Premium
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.
The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.
Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
Premium
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.